Salt Lake City, UT – According to filings with the U.S. Securities and Exchange Commission, ePurines is raising $5,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Bellamkonda Kishore played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ePurines

ePurines, Inc is a drug development company focused on innovative purinergic-based therapies for obesity, metabolic syndrome renal and liver diseases. The core technologies of the ePurines were developed in the VA labs and are patented by the US Department of Veterans Affairs. ePurines’ value proposition is leveraging its purinergic signaling platform and expertise to target diseases affecting the US Veterans and the general population.

To learn more about ePurines, visit http://www.epurines.com/

Contact:
Bellamkonda Kishore, President and Chief Executive Officer
801-598-3389
https://www.linkedin.com/in/bkishore369/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved